An observational study in End Stage Renal Disease, Cardio-Renal Syndrome and Myocardial Infarction, sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Queen Mary University of London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Kidney Failure, Chronic with a site in United Kingdom — 15 open to participants now, 23 under way, 5 of them phase 3. Kidney Failure, Chronic · United Kingdom.
Among the 103 studies in Kidney Failure, Chronic with a site in United Kingdom, this one has the largest planned enrollment of the 26 observational ones that give a count, is one of 8 that started in 2024, is one of 26 observational ones, reaches primary completion later than 19 of the 22 other live ones, and was the 100th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →15 of the 103 studies in Kidney Failure, Chronic with a site in United Kingdom are open now. Recruiting first, the newest first:
East and North Hertfordshire NHS Trust · Sites in United Kingdom
Ages 18+
East and North Hertfordshire NHS Trust · Sites in United Kingdom
CSL Behring · Sites in United Kingdom, United States, Argentina and 32 more countries
Ages 18+
W.L.Gore & Associates · Sites in United Kingdom, Germany, Italy
Ages 18+
Hansa Biopharma AB · Sites in United Kingdom, Finland, France and 3 more countries
Ages 1–17
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 19 · Phase 4 5
First in 1994; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60,000 is above the median of 120 across 445 observational studies indexed under Kidney Failure, Chronic.
Median enrollment 80 across the 77 interventional studies, 94 across the 26 observational. Of the 72 that completed or were terminated, 22 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.
Queen Mary University of London has 2 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
8 of the studies in Kidney Failure, Chronic with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT03994471Phase 3Iperboreal Pharma SrlEfficacy and Safety of XyloCore Peritoneal Dialysis Solution. | 2026-12-31 |
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT07713680East and North Hertfordshire NHS Trustβ2M Post-HD Rebound Prediction | 2026-11 |
| NCT02823821University of SydneyRandomised Evaluation of Sodium Dialysate Levels on Vascular Events | 2026-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 103 studies in Kidney Failure, Chronic with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \<60 mL/min/1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the "treatment risk paradox," has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population.
This data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.
This study will include all patients admitted to or reviewed at The Royal London Hospital (RLH) who have renal disease. These patients range from young adults to the elderly and will include any patient ≥16 years of age. Patients will include those who have end stage renal disease, seen in the low clearance clinic, are on dialysis, are on the renal transplant list and who are post renal transplant.
Patients will be included from referrals made by other clinicians either as in or outpatients. All these patients have their clinical data captured on a database or hospital based clinical programme.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Nephrology team.
Inclusion Criteria:
Exclusion Criteria:
1. Patients \<16 years will not be included in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study aims to assess, in a real-world setting, the safety, efficacy and feasibility of further investigations in patients with renal disease and cardiac disease.
Other: Observation
Observation
Mortality
Time frame: 30 days and 1 year
Re-admission rates
Time frame: 30 days and 1 year
Major Adverse Cardiac Events
Time frame: 30 days and 1 year
Major Adverse Kidney Events
Time frame: 30 days and 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Jun 2030, 70 months after the start.
Of 132 non-industry observational studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 62. This study's planned 70 months is above that.
Counting every sponsor, half of 151 studies reached it within 29 months; a quarter within 11 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London →